Longitudinal efficacy and safety of capecitabine and cyclophosphamide as early-line treatment in patients with metastatic breast cancer: A prospective cohort study by the Kyushu Breast Cancer Study Group, Japan.-Reference-Cited by-同舟云学术

Longitudinal efficacy and safety of capecitabine and cyclophosphamide as early-line treatment in patients with metastatic breast cancer: A prospective cohort study by the Kyushu Breast Cancer Study Group, Japan.

Published:2022-01-31 Issue:1 Volume:30 Page:38-44
ISSN:1344-6835
Container-title:Annals of Cancer Research and Therapy
language:en
Short-container-title:Ann. Cancer Res. Therap.

Author:

Mashino Kohjiro¹,Tanaka Maki²,Yamaguchi Miki²,Nishimura Reiki³,Yamamoto Yutaka⁴,Ueo Hiroaki⁵,Tanaka Toshihiro⁶,Koga Kenichiro⁷,Yoshiyama Tomoyuki⁸,Mitsuyama Shoshu⁷,Tamura Kazuo⁶,Kyushu Breast Cancer Study Group

Affiliation:

1. Department of Breast Surgery, Oita Prefectural Hospital

2. Department of Breast Surgery, JCHO Kurume General Hospital

3. Department of Breast Oncology, Kumamoto Shinto General Hospital

4. Department of Breast and Endocrine Surgery, Kumamoto University Hospital

5. Department of Surgery, Ueo Breast Cancer Hospital

6. Division of Oncology, Hematology, and Infectious Diseases, Department of Internal Medicine, Fukuoka University

7. Department of Surgery, Kitakyushu Municipal Medical Center

8. Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center

Publisher

The Japanese Society of Strategies for Cancer Research and Therapy

Subject